Ignite Creation Date:
2024-07-17 @ 10:44 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06500702
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-07-08
Brief Title:
A Study to Evaluate the Efficacy and Safety of Frexalimab SAR442970 or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Sponsor:
Sanofi
Organization:
Sanofi
Organization Data
Organization:
Sanofi
Class:
INDUSTRY
Study ID:
ACT18064
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Sanofi
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None